Role of vascular smooth muscle cell in the inflammation of atherosclerosis

BMB Reports

Volumn 47, Issue 1, 2014, Pages 1-7

  Lim, Soyeon ^a   Park, Sungha ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE;

ATHEROSCLEROSIS; CYTOLOGY; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY; SHORT SURVEY; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; CYTOKINES; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, CELL SURFACE;

EID: 84893374765     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2014.47.1.285     Document Type: Short Survey

References (71)

1. Pidkovka, N. A., Cherepanova, O. A., Yoshida, T., Alexander, M. R., Deaton, R. A., Thomas, J. A., Leitinger, N. and Owens, G. K. (2007) Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ. Res. 101, 792-801.
2. Berliner, J. A. and Watson, A. D. (2005) A role for oxidized phospholipids in atherosclerosis. N. Engl. J. Med. 353, 9-11.
3. Libby, P., Ridker, P. M. and Hansson, G. K. (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325.
4. Lacolley, P., Regnault, V., Nicoletti, A., Li, Z. and Michel, J. B. (2012) The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc. Res. 95, 194-204.
5. Boyle, J. J., Weissberg, P. L. and Bennett, M. R. (2003) Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler. Thromb. Vasc. Biol. 23, 1553-1558.
6. Gough, P. J., Gomez, I. G., Wille, P. T. and Raines, E. W. (2006) Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest. 116, 59-69.
7. Johnson, J. L., Devel, L., Czarny, B., George, S. J., Jackson, C. L., Rogakos, V., Beau, F., Yiotakis, A., Newby, A. C. and Dive, V. (2011) A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler. Thromb. Vasc. Biol. 31, 528-535.
8. Mehta, P. K. and Griendling, K. K. (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell. Physiol. 292, 82-97.
9. Williams, B. (2001) Angiotensin II and the pathophysiology of cardiovascular remodeling. Am. J. Cardiol. 87, 10-17.
10. Ferrario, C. M. (2006) Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J. Renin Angiotensin Aldosterone Syst. 7, 3-14.
11. Park, W. K., Regoli, D. and Rioux, F. (1973) Characterization of angiotensin receptors in vascular and intestinal smooth muscles. Br. J. Pharmacol. 48, 288-301.
12. Lee, D., Lee, K. H., Park, H., Kim, S. H., Jin, T., Cho, S., Chung, J. H., Lim, S. and Park, S. (2013) The effect of soluble RAGE on inhibition of angiotensin II-mediated atherosclerosis in apolipoprotein E deficient mice. PloS One 8, e69669.
13. Cai, Q., Lanting, L. and Natarajan, R. (2004) Growth factors induce monocyte binding to vascular smooth muscle cells: implications for monocyte retention in atherosclerosis. American journal of physiology. Am. J. Physiol. Cell Physiol. 287, 707-714.
14. Rateri, D. L., Moorleghen, J. J., Knight, V., Balakrishnan, A., Howatt, D. A., Cassis, L. A. and Daugherty, A. (2012) Depletion of endothelial or smooth muscle cell-specific angiotensin II type 1a receptors does not influence aortic aneurysms or atherosclerosis in LDL receptor deficient mice. PloS One 7, e51483.
15. Rateri, D. L., Moorleghen, J. J., Balakrishnan, A., Owens, A. P. 3rd, Howatt, D. A., Subramanian, V., Poduri, A., Charnigo, R., Cassis, L. A. and Daugherty, A. (2011) Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/-mice. Circ. Res. 108, 574-581.
16. Doggrell, S. A. (2002) Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? Expert Opin. Pharmacother. 11, 1543-1556.
17. Schmidt, B., Drexler, H. and Schieffer, B. (2004) Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution of mechanisms other than AT1 receptor blockade. Am. J. Cardiovasc. Drugs. 4, 361-368.
18. Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., Wang, F., Pan, Y. C., Elliston, K., Stern, D. and Shaw, A. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267, 14998-15004.
19. Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., Morser, J., Stern, D. and Schmidt, A. M. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270, 25752-25761.
20. Heizmann, C. W., Ackermann, G. E. and Galichet, A. (2007) Pathologies involving the S100 proteins and RAGE. Subcell. Biochem. 45, 93-138.
21. Brett, J., Schmidt, A. M., Yan, S. D., Zou, Y. S., Weidman, E., Pinsky, D., Nowygrod, R., Neeper, M., Przysiecki, C., Shaw, A., Migheli, A. and Stern, D. (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143, 1699-1712.
22. Kirstein, M., Brett, J., Radoff, S., Ogawa, S., Stern, D. and Vlassara, H. (1990) Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. U. S. A. 87, 9010-9014.
23. Esposito, C., Gerlach, H., Brett, J., Stern, D. and Vlassara, H. (1989) Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J. Exp. Med. 170, 1387-1407.
24. Hudson, B. I., Bucciarelli, L. G., Wendt, T., Sakaguchi, T., Lalla, E., Qu, W., Lu, Y., Lee, L., Stern, D. M., Naka, Y., Ramasamy, R., Yan, S. D., Yan, S. F., D'Agati, V. and Schmidt, A. M. (2003) Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch. Biochem. Biophys. 419, 80-88.
25. Hayakawa, E., Yoshimoto, T., Sekizawa, N., Sugiyama, T. and Hirata, Y. (2012) Overexpression of receptor for advanced glycation end products induces monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cell line. J. Atheroscler. Thromb. 19, 13-22.
26. Jaulmes, A., Thierry, S., Janvier, B., Raymondjean, M. and Marechal, V. (2006) Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta. FASEB J. 20, 1727-1729.
27. Lippai, D., Bala, S., Petrasek, J., Csak, T., Levin, I., Kurt-Jones, E. A. and Szabo, G. (2013) Alcohol-induced IL-1beta in the brain is mediated by NLRP3/ASC in flammasome activation that amplifies neuroinflammation. J. leukoc. Biol. 94, 171-182.
28. Bae, J.-S. and Rezaie, A. R. (2013) Thrombin inhibits HMGB1-mediated proinflammatory signaling responses when endothelial protein C receptor is occupied by its natural ligand. BMB Rep. 46, 544-549.
29. Kokkola, R., Andersson, A., Mullins, G., Ostberg, T., Treutiger, C. J., Arnold, B., Nawroth, P., Andersson, U., Harris, R. A. and Harris, H. E. (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol. 61, 1-9.
30. Toure, F., Fritz, G., Li, Q., Rai, V., Daffu, G., Zou, Y. S., Rosario, R., Ramasamy, R., Alberts, A. S., Yan, S. F. and Schmidt, A. M. (2012) Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. Circ. Res. 110, 1279-1293.
31. Menini, S., Iacobini, C., Ricci, C., Blasetti Fantauzzi, C., Salvi, L., Pesce, C. M., Relucenti, M., Familiari, G., Taurino, M. and Pugliese, G. (2013) The galectin-3/RAGE dyad modulatesvascular osteogenesis in atherosclerosis. Cardiovasc. Res. 100, 472-480.
32. Kim, J. K., Park, S., Lee, M. J., Song, Y. R., Han, S. H., Kim, S. G., Kang, S. W., Choi, K. H., Kim, H. J. and Yoo, T. H. (2012) Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 220, 208-214.
33. Goldstein, J. L. and Brown, M. S. (1975) Lipoprotein receptors, cholesterol metabolism, and atherosclerosis. Arch. Pathol. 99, 181-184.
34. Nestel, P. J. (1980) Lipoprotein protein receptors and their relation to atherosclerosis. Circ. Res. 46, I106-109.
35. Kowala, M. C., Recce, R., Beyer, S., Gu, C. and Valentine, M. (2000) Characterization of atherosclerosis in LDL receptor knockout mice: macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis 149, 323-330.
36. Basak, J. M., Verghese, P. B., Yoon, H., Kim, J. and Holtzman, D. M. (2012) Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. J. Biol. Chem. 287, 13959-13971.
37. Naderi, G. A., Asgary, S., Sarraf-Zadegan, N. and Shirvany, H. (2003) Anti-oxidant effect of flavonoids on the susceptibility of LDL oxidation. Mol. Cell. Biochem. 246, 193-196.
38. Basu, S. K., Brown, M. S., Ho, Y. K. and Goldstein, J. L. (1979) Degradation of low density lipoprotein. dextran sulfate complexes associated with deposition of cholesteryl esters in mouse macrophages. J. Biol. Chem. 254, 7141-7146.
39. Sun, Y. and Chen, X. (2011) Ox-LDL-induced LOX-1 expression in vascular smooth muscle cells: role of reactive oxygen species. Funda. Clin. Pharmacol. 25, 572-579.
40. Sawamura, T., Kume, N., Aoyama, T., Moriwaki, H., Hoshikawa, H., Aiba, Y., Tanaka, T., Miwa, S., Katsura, Y., Kita, T. and Masaki, T. (1997) An endothelial receptor for oxidized low-density lipoprotein. Nature 386, 73-77.
41. Hofnagel, O., Luechtenborg, B., Stolle, K., Lorkowski, S., Eschert, H., Plenz, G. and Robenek, H. (2004) Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 24, 1789-1795.
42. Limor, R., Kaplan, M., Sawamura, T., Sharon, O., Keidar, S., Weisinger, G., Knoll, E., Naidich, M. and Stern, N. (2005) Angiotensin II increases the expression of lectin-like oxidized low-density lipoprotein receptor-1 in human vascular smooth muscle cells via a lipoxygenase-dependent pathway. Am. J. Hypertens. 18, 299-307.
43. Hofnagel, O., Luechtenborg, B., Eschert, H., Weissen-Plenz, G., Severs, N. J. and Robenek, H. (2006) Pravastatin inhibits expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins. Arterioscler. Thromb. Vasc. Biol. 26, 604-610.
44. Morawietz, H. (2007) LOX-1 and atherosclerosis: proof of concept in LOX-1-knockout mice. Circ. Res. 100, 1534-1536.
45. Cole, J. E., Georgiou, E. and Monaco, C. (2010) The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm. 2010, 393946.
46. Edfeldt, K., Swedenborg, J., Hansson, G. K. and Yan, Z. Q. (2002) Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105, 1158-1161.
47. Curtiss, L. K. and Tobias, P. S. (2009) Emerging role of Toll-like receptors in atherosclerosis. J. Lipid Res. 50 (Suppl), 340-345.
48. Yang, X., Coriolan, D., Schultz, K., Golenbock, D. T. and Beasley, D. (2005) Toll-like receptor 2 mediates persistent chemokine release by Chlamydia pneumoniae-infected vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 25, 2308-2314.
49. Schoneveld, A. H., Oude Nijhuis, M. M., van Middelaar, B., Laman, J. D., de Kleijn, D. P. and Pasterkamp, G. (2005) Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovas. Res. 66, 162-169.
50. Madan, M. and Amar, S. (2008) Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings. PloS One 3, e3204.
51. de Graaf, R., Kloppenburg, G., Kitslaar, P. J., Bruggeman, C. A. and Stassen, F. (2006) Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes Infect. 8, 1859-1865.
52. Lee, G. L., Chang, Y. W., Wu, J. Y., Wu, M. L., Wu, K. K., Yet, S. F. and Kuo, C. C. (2012) TLR 2 induces vascular smooth muscle cell migration through cAMP response element-binding protein-mediated interleukin-6 production. Arterioscler. Thromb. Vasc. Biol. 32, 2751-2760.
53. Lee, J. H., Joo, J. H., Kim, J., Lim, H. J., Kim, S., Curtiss, L., Seong, J. K., Cui, W., Yabe-Nishimura, C. and Bae, Y. S. (2013) Interaction of NADPH oxidase 1 with Toll-like receptor 2 induces migration of smooth muscle cells. Cardiovas. Res. 99, 483-493.
54. Yang, X., Coriolan, D., Murthy, V., Schultz, K., Golenbock, D. T. and Beasley, D. (2005) Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am. J. Physiol. Heart. Circ. Physiol. 289, 1069-1076.
55. Heo, S. K., Yun, H. J., Noh, E. K., Park, W. H. and Park, S. D. (2008) LPS induces inflammatory responses in human aortic vascular smooth muscle cells via Toll-like receptor 4 expression and nitric oxide production. Immunol. Lett. 120, 57-64.
56. Li, H., Xu, H. and Sun, B. (2012) Lipopolysaccharide regulates MMP-9 expression through TLR4/NF-kappaB signaling in human arterial smooth muscle cells. Mol. Med. Rep. 6, 774-778.
57. Hayashi, C., Papadopoulos, G., Gudino, C. V., Weinberg, E. O., Barth, K. R., Madrigal, A. G., Chen, Y., Ning, H., LaValley, M., Gibson, F. C. 3rd, Hamilton, J. A. and Genco, C. A. (2012) Protective role for TLR4 signaling in atherosclerosis progression as revealed by infection with a common oral pathogen. J. Immunol. 189, 3681-3688.
58. Delbridge, L. M. and O'Riordan, M. X. (2007) Innate recognition of intracellular bacteria. Curr. Opin. Immunol. 19, 10-16.
59. Bracey, N. A., Beck, P. L., Muruve, D. A., Hirota, S. A., Guo, J., Jabagi, H., Wright, J. R. Jr., Macdonald, J. A., Lees-Miller, J. P., Roach, D., Semeniuk, L. M. and Duff, H. J. (2013) The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. Exp. Physiol. 98, 462-472.
60. Srinivasula, S. M., Poyet, J. L., Razmara, M., Datta, P., Zhang, Z. and Alnemri, E. S. (2002) The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J. Biol. Chem. 277, 21119-21122.
61. Behrends, C., Sowa, M. E., Gygi, S. P. and Harper, J. W. (2010) Network organization of the human autophagy system. Nature 466, 68-76.
62. Shi, C. S., Shenderov, K., Huang, N. N., Kabat, J., Abu-Asab, M., Fitzgerald, K. A., Sher, A. and Kehrl, J. H. (2012) Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat. Immunol. 13, 255-263.
63. Nakahira, K., Haspel, J. A., Rathinam, V. A., Lee, S. J., Dolinay, T., Lam, H. C., Englert, J. A., Rabinovitch, M., Cernadas, M., Kim, H. P., Fitzgerald, K. A., Ryter, S. W. and Choi, A. M. (2011) Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12, 222-230.
64. Shimabukuro, M., Hirata, Y., Tabata, M., Dagvasumberel, M., Sato, H., Kurobe, H., Fukuda, D., Soeki, T., Kitagawa, T., Takanashi, S. and Sata, M. (2013) Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 33, 1077-1084.
65. Zuurbier, C. J., Jong, W. M., Eerbeek, O., Koeman, A., Pulskens, W. P., Butter, L. M., Leemans, J. C. and Hollmann, M. W. (2012) Deletion of the innate immune NLRP3 receptor abolishes cardiac ischemic preconditioning and is associated with decreased Il-6/STAT3 signaling. PloS One 7, e40643.
66. Li, Y., Xu, S., Jiang, B., Cohen, R. A. and Zang, M. (2013) Activation of sterol regulatory element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in diabetic pigs. PloS One 8, e67532.
67. Menu, P., Pellegrin, M., Aubert, J. F., Bouzourene, K., Tardivel, A., Mazzolai, L. and Tschopp, J. (2011) Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis. 2, e137.
68. Qiao, Y., Wang, P., Qi, J., Zhang, L. and Gao, C. (2012) TLR-induced NF-kappaB activation regulates NLRP3 expression in murine macrophages. FEBS Lett. 586, 1022-1026.
69. Xiao, H., Lu, M., Lin, T. Y., Chen, Z., Chen, G., Wang, W. C., Marin, T., Shentu, T. P., Wen, L., Gongol, B., Sun, W., Liang, X., Chen, J., Huang, H. D., Pedra, J. H., Johnson, D. A. and Shyy, J. Y. (2013) Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation 128, 632-642.
70. Shi, Z. D. and Tarbell, J. M. (2011) Fluid flow mechanotransduction in vascular smooth muscle cells and fibroblasts. Ann. Biomed. Eng. 39, 1608-1619.
71. Tedgui, A. and Mallat, Z. (2001) Anti-inflammatory mechanisms in the vascular wall. Circ. Res. 88, 877-887.